

ZEJULA DIARY

To support you at each step of your **ZEJULA** treatment

This diary is for use in conjunction with the patient booklet and the ZEJULA Consumer Medicine Information.



Treatment diary to support you at each step

As you embark on this journey, remember that knowledge is your ally. With this treatment diary and the associated ZEJULA patient booklet, you are equipped to face challenges, look after your wellbeing, and ultimately, embrace a sense of empowerment during your path forward.

The diary is not intended to take the place of information and advice provided to you by your healthcare professional team, but to supplement it. Please read the ZEJULA Consumer Medicine Information (CMI) leaflet provided to you by your doctor. The CMI is also available from www.medsafe.govt.nz/consumers/cmi/z/zejula.pdf. Should you have further questions and/or concerns about your treatment or about your condition, please speak with your healthcare professional.



This diary is a dedicated space to document your experiences, and to empower you with knowledge and to help keep you organised.

This diary can help you:



To Track

Medical tests and symptoms that can help to monitor the effectiveness and/or side effects of your treatment.



To Record

In this section, you will have a record that can be shared with your healthcare professionals.








How you will be monitored during treatment with ZEJULA

Your healthcare professional will regularly check important parameters to monitor how your body is responding to **ZEJULA** and to help them make any necessary changes to your dose or treatment. It is important that you follow your doctor's advice and have any tests on time.

Monitoring Schedule¹





Sometimes people taking **ZEJULA** need to have a short break from treatment, of up to 4 weeks, even if they feel well. Your doctor will monitor you during this time and will determine when you can resume taking **ZEJULA** and at what dose. Following this, you may be asked to make adjustments in the schedule of your blood tests.¹

Monitoring Summary

To help you keep track of your routine monitoring results, you can add your blood count, blood pressure and heart rate information into the table on page 9. This can then be easily shared with you healthcare professional.

Monitoring Summary

ZEJULA DOSE

ے ا	

If you have questions you can speak with your doctor, nurse or pharmacist.

HEALTHCARE TEAM CONTACT DETAILS

DATE/TIME	FULL BLOOD COUNT	BLOOD PRESSURE	HEART RATE

DATE/TIME	FULL BLOOD COUNT	BLOOD PRESSURE	HEART RATE

Medical Appointments

NAME	DATE	TIME

12



Always seek advice from a healthcare professional about any side effects you experience.2

Tell your healthcare professional immediately if you notice any of the following signs of potentially serious side effects:

- Bruising or bleeding for longer than usual when you hurt yourself - these may be signs of a low blood platelet count (thrombocytopenia)
- Being short of breath, feeling very tired, having pale skin, or fast heartbeat - these may be signs of a low red blood cell count (anaemia)
- Fever or infection these may be signs of a low white blood cell count (neutropenia)
- Allergic reaction (hypersensitivity, including anaphylaxis)
- $\begin{array}{c} + \\ \\ \end{array}$ Life-threatening allergic reaction (such as difficulty breathing, low blood pressure, and/or organ failure)

What to do if you miss a dose:2



ZEJULA should be used regularly at the same time each day. If you forget to take ZEJULA, skip the dose you missed and take your next dose when you are meant to.

Do not take a double dose to make up for the dose you missed.

Potential side effects²

All medications have some side effects. Being aware of these may help you better prepare to manage them with your healthcare professional. It is important to let your healthcare professional know if you experience any side effects as they will have ways to help you address them.

Tell your healthcare professional if you notice any of these very common side effects. They are usually mild and short-lived.

- Feeling like your heart is skipping beats or beating harder than usual
- Feeling sick
- Constipation
- Vomiting
- Stomach pain
- Feeling of weakness
- Diarrhoea
- Indigestion
- High blood pressure

- Tiredness
- Decreased appetite
- Urinary tract infection
- Shortness of breath
- Cough
- Runny or stuffy nose
- Headache
- Dizziness
- Inability to sleep
- Pain in the joints, muscles, and back



It is important you maintain an open dialogue with your healthcare professional team, as there may be nurses and pharmacists that should be involved more regularly.

In this section, you can capture the details of the other medicines you are currently taking, so you have a record that can be shared with your healthcare professionals.

My Medications

Ty Wicalcations				
IAME	DOSE		NAME	DOSE
VHAT IS IT FOR?			WHAT IS IT FOR?	
]		
IAME	DOSE		NAME	DOSE
VHAT IS IT FOR?			WHAT IS IT FOR?	
IAME	DOSE		NAME	DOSE
VHAT IS IT FOR?			WHAT IS IT FOR?	
IAME	DOSE		NAME	DOSE
VHAT IS IT FOR?			WHAT IS IT FOR?	

Notes	Notes

References

- 1. ZEJULA NZ Data Sheet GlaxoSmithKline New Zealand. ZEJULA Data Sheet. GSK NZ; 2024.
- 2. ZEJULA Consumer Medicine Information GlaxoSmithKline New Zealand. ZEJULA CMI 2024. Available at: https://www.medsafe.govt.nz/Consumers/CMI/z/zejula.pdf





ZEJULA (niraparib: 100mg capsules and tablets) is a prescription medicine used in adults for the treatment of cancer of the ovary, the fallopian tubes or the peritoneum. It is used for the treatment of cancer that has responded to first treatment with platinum-based chemotherapy or come back (recurred) after the cancer has responded to previous treatment with standard platinum-based chemotherapy. ZEJULA is fully funded for the treatment of advanced and recurrent ovarian cancer; Special Authority criteria apply. ZEJULA has risks and benefits and should be initiated and supervised by a doctor experienced in the use of anticancer medicines. Ask your doctor if ZEJULA is right for you. If your symptoms worsen or you have side effects, see your doctor, pharmacist or healthcare professional. Use strictly as directed. Normal doctor charges apply. Additional product information and Consumer Medicine Information (CMI) is available at www.medsafe.govt.nz. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Marketed by GlaxoSmithKline NZ Ltd, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500. TAPS NP21919 NP-NZ-NRP-BKLT-240002 Date of Approval: 12 2024 Date of Expiry: 12 2026